1. Home
  2. ADAG vs EDAP Comparison

ADAG vs EDAP Comparison

Compare ADAG & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adagene Inc.

ADAG

Adagene Inc.

N/A

Current Price

$3.78

Market Cap

146.3M

Sector

Health Care

ML Signal

N/A

Logo EDAP TMS S.A.

EDAP

EDAP TMS S.A.

N/A

Current Price

$3.85

Market Cap

163.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADAG
EDAP
Founded
2011
1979
Country
China
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
146.3M
163.4M
IPO Year
2020
1998

Fundamental Metrics

Financial Performance
Metric
ADAG
EDAP
Price
$3.78
$3.85
Analyst Decision
Strong Buy
Buy
Analyst Count
4
3
Target Price
$8.00
$8.50
AVG Volume (30 Days)
222.3K
44.2K
Earning Date
03-24-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3,688.61
N/A
Revenue Next Year
$17.39
$7.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.33
$1.21
52 Week High
$4.58
$5.05

Technical Indicators

Market Signals
Indicator
ADAG
EDAP
Relative Strength Index (RSI) 55.10 44.61
Support Level $1.69 $3.51
Resistance Level $4.58 $4.32
Average True Range (ATR) 0.47 0.33
MACD -0.00 -0.05
Stochastic Oscillator 44.97 49.04

Price Performance

Historical Comparison
ADAG
EDAP

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Share on Social Networks: